依奇珠单抗治疗对中度至重度斑块状银屑病患者心血管参数呈中性影响:UNCOVER-1、UNCOVER-2和UNCOVER-3研究结果
基于三项3期试验,中度至重度斑块状银屑病患者诱导期随机接受安慰剂、依奇珠单抗或依那西普,应答者维持期再随机接受安慰剂或依奇珠单抗至60周。结果显示依奇珠单抗对血脂、血糖、血压及低密度脂蛋白与高密度脂蛋白比值等心血管相关参数呈中性影响,hsCRP在12周显著降低但60周降低未达显著。
要点
- 维持期至60周,依奇珠单抗组总胆固醇、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇、极低密度脂蛋白胆固醇、甘油三酯、载脂蛋白A1、载脂蛋白B、空腹血糖及收缩压/舒张压与安慰剂组相比无显著变化。
- 低密度脂蛋白与高密度脂蛋白比值在诱导期和维持期保持稳定。
- hsCRP浓度在12周较安慰剂显著降低,60周时仍降低但未达统计学显著。
核心结论
- 依奇珠单抗对银屑病患者心血管相关参数呈中性影响。
研究设计与样本
- 3期试验中,中度至重度银屑病患者在诱导期(第0-12周;UNCOVER-1、UNCOVER-2和UNCOVER-3)随机接受安慰剂、依奇珠单抗或依那西普治疗。
- 第12周时,应答者再随机接受安慰剂或依奇珠单抗至维持期(第12-60周;UNCOVER-1和UNCOVER-2)。
- 获取至60周的实验室指标(空腹血脂谱、血糖或高敏C反应蛋白[hsCRP]水平)、体重、血压和心电图。
主要发现
- 基线参数除甘油三酯和hsCRP水平升高外均在正常范围内。
- 维持期给药后,至60周时总胆固醇、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇、极低密度脂蛋白胆固醇、甘油三酯、载脂蛋白A1、载脂蛋白B、空腹血糖水平及收缩压/舒张压与安慰剂相比均无显著变化。
- 低密度脂蛋白与高密度脂蛋白比值在诱导期和维持期保持稳定。
- hsCRP浓度在12周较安慰剂显著降低,60周时仍降低但未达统计学显著。
- 诱导期部分参数出现一过性变化,但未持续至维持期。
局限性
- 缺乏超声心动图评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The impact of ixekizumab treatment for psoriasis on cardiovascular-related parameters in patients is unknown. OBJECTIVE: To investigate cardiovascular-related parameters in patients with psoriasis treated with ixekizumab. METHODS: In phase 3 trials, patients with moderate-to-severe psoriasis were randomized and treated with placebo, ixekizumab, or etanercept during the induction period (weeks 0-12; UNCOVER-1, UNCOVER-2, and UNCOVER-3). At week 12, responders were rerandomized to receive placebo or ixekizumab through the maintenance period (weeks 12-60; UNCOVER-1 and UNCOVER-2). Laboratory measures (fasting lipid profiles, glucose level, or high-sensitivity C-reactive protein [hsCRP] level), weight, blood pressure, and electrocardiograms were obtained through 60 weeks. RESULTS: Baseline parameters were within normal ranges with the exception of elevated triglyceride and hsCRP levels. After maintenance dosing, no significant changes were observed versus placebo for total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, very-low-density lipoprotein cholesterol, triglyceride, apolipoprotein A1, apolipoprotein B, or fasting glucose levels or for systolic/diastolic blood pressure at 60 weeks. Importantly, low-density lipoprotein-to-high-density lipoprotein ratios remained stable during the induction and maintenance periods. HsCRP concentrations were significantly reduced versus placebo at 12 weeks and remained reduced at 60 weeks, although not significantly. Although transient changes were observed for some parameters during the induction period, these changes did not persist into the maintenance period. LIMITATIONS: A lack of echocardiogram evaluations. CONCLUSIONS: Ixekizumab had a neutral impact on cardiovascular-related parameters in patients with psoriasis.
引用
- Egeberg A, Wu JJ, Korman N, et al. Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3. J Am Acad Dermatol. 2018. PMID: 29548945. doi:10.1016/j.jaad.2018.02.074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。